A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment is a research paper published in Contemporary Clinical Trials Communications (2023). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
U.S. Department of Defense
Grant: W81XWH-15-1-0645
Avanir Pharmaceuticals
Grant: SRX246
National Institutes of Health
Grant: UL1TR002384
National Institutes of Health
Grant: 5UL1TR002384-03
Clinical and Translational Science Center
National Center for Advancing Translational Sciences
Fields of Study
Keywords
Sustainable Development Goals